Farletuzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | FR-alpha |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
896723-44-7  |
| ChemSpider | none |
| UNII |
2O09BG0OWA  |
| KEGG |
D09343 |
| Chemical and physical data | |
| Formula | C6466H9928N1716O2020S42 |
| Molar mass | 145.4 kg/mol |
| (what is this?) (verify) | |
Farletuzumab (MORAb-003) is a monoclonal antibody[1] which is being investigated for the treatment of ovarian cancer.[2][3]
This drug was developed by Morphotek, Inc.
It is targeted at FR-alpha which is overexpressed in some cancers such as ovarian cancer.
References
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Farletuzumab, American Medical Association.
- ↑ ClinicalTrials.gov: Phase II Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
- ↑ ClinicalTrials.gov: Phase III Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
This article is issued from Wikipedia - version of the 9/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.